Abstract:The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread worldwide and has had unprecedented effects in healthcare systems, economies and society. COVID-19 clinical presentation primarily affects the respiratory system causing bilateral pneumonia, but it is increasingly being recognized as a systemic disease, with neurologic manifestations reported in patients with mild symptoms but, most frequently, in those in a severe condition. Elderly individuals are at high risk of developing severe forms of COVID-19 due to factors associated with aging and a higher prevalence of medical comorbidities and, therefore, they are more vulnerable to possible lasting neuropsychiatric and cognitive impairments. Several reports have described insomnia, depressed mood, anxiety, post-traumatic stress disorder and cognitive impairment in a proportion of patients after discharge from the hospital. The potential mechanisms underlying these symptoms are not fully understood but are probably multifactorial, involving direct neurotrophic effect of SARS-CoV-2, consequences of long intensive care unit stays, the use of mechanical ventilation and sedative drugs, brain hypoxia, systemic inflammation, secondary effects of medications used to treat COVID-19 and dysfunction of peripheral organs. Chronic diseases such as dementia are a particular concern not only because they are associated with higher rates of hospitalization and mortality but also because COVID-19 further exacerbates the vulnerability of those with cognitive impairment. In patients with dementia, COVID-19 frequently has an atypical presentation with mental status changes complicating the early identification of cases. COVID-19 has had a dramatical impact in long-term care facilities, where rates of infection and mortality have been very high. Community measures implemented to slow the spread of the virus have forced to social distancing and cancelation of cognitive stimulation programs, which may have contributed to generate loneliness, behavioral symptoms and worsening of cognition in patients with dementia. COVID-19 has impacted the functioning of Memory Clinics, research programs and clinical trials in the Alzheimer's field, triggering the implementation of telemedicine. COVID-19 survivors should be periodically evaluated with comprehensive cognitive and neuropsychiatric assessments, and specific mental health and cognitive rehabilitation programs should be provided for those suffering long-term cognitive and psychiatric sequelae.

Cognitive dysfunction associated with COVID-19: Prognostic role of circulating biomarkers and microRNAs

Role of microRNAs in cognitive decline related to COVID‐19 (Review)

Neurovascular coupling impairment as a mechanism for cognitive deficits in COVID-19

Cytokine Storm and Neuropathological Alterations in Patients with Neurological Manifestations of COVID-19

Cognitive Impairment in the Post-Acute Phases of COVID-19 and Mechanisms: an Introduction and Narrative Review

COVID-19 associated cognitive impairment: A systematic review

Cognitive impact of COVID-19: looking beyond the short term

Clinical and CSF single-cell profiling of post-COVID-19 cognitive impairment

Neuropsychological, plasma marker, and functional connectivity changes in Alzheimer's disease patients infected with COVID-19

Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment

Neuropsychological, Plasma Marker, and Functional Connectivity Changes in Alzheimer’s Disease Patients Infected with COVID-19

Neurological Complications of COVID-19: Unraveling the Pathophysiological Underpinnings and Therapeutic Implications

Brain microstructure and connectivity in COVID-19 patients with olfactory or cognitive impairment

Neurochemical biomarkers to study CNS effects of COVID-19: A narrative review and synthesis

Neuroinflammation in Post COVID‐19 Sequelae: Neuroinvasion and Neuroimmune Crosstalk

An overview of prognostic value of neurologic and cardiac biomarkers in patients with COVID-19 sequelae

Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19

Brain Pathology in COVID-19: Clinical Manifestations and Potential Mechanisms

Blood brain barrier disruption and glutamatergic excitotoxicity in post-acute sequelae of SARS COV-2 infection cognitive impairment: potential biomarkers and a window into pathogenesis

Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia

Long COVID and its association with neurodegenerative diseases: pathogenesis, neuroimaging, and treatment